Euretos Analytics confirmed by clinical study linking leukemia chemotherapy to osteonecrosis
Monday 25 January 2016
Osteonecrosis (bone tissue death) is a side effect of chemotherapy in about 15% of acute lymphoblastic leukemia (ALL) patients. A recent publication in the journal Blood found that ALL patients having a defect on the BMP7 gene were 8 to 15 times more likely to develop osteonecrosis. The BMP7 gene plays an important role in bone tissue creation.
Using the Euretos (re)Search application application to do a gene - disease analysis, it becomes immediately clear that, although until the publication no direct interaction was known, the indirect interactions between BMP7 and osteonecrosis are very strong. When compared to existing gene-disease interactions, the BMP7-osteonecrosis interaction profile ranks among the 85% strongest! Especially interesting is the fact that multiple chemicals commonly used in chemotherapy were found, such as carmustine, cyclosporine, tretinoin and vesanoid, that inhibit the working of the BMP7 gene.
In this analysis over 350 indirect biological interactions via disorders, anatomy, genes, molecules and physiology were found and assessed. These interactions would be very difficult and time consuming to find, one by one, using traditional search approaches and provide excellent angles for further research into this promising mechanism.
The Euretos Knowledge Platform connects over 9 million known phenotypic, genetic, proteomic, metabolic and chemical concepts in a single ultra-performance environment. All content is directly derived from scientific literature and databases with full references to sources. Apart from scope and performance, the Euretos Knowledge Platform is unique in providing the similarity, specificity and interaction strength of all its connections, even predicting their likelihood if not existing. This truly enables better answers to research questions. Faster.